Innate Pharma SA
IPHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001598599
No open-market purchases or sales by Innate Pharma SA insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $354.0K in total; no superinvestor holds it.
Other share classesIPHYF
Q4 2025 vs. Q3 2025
How the institutions holding Innate Pharma SA changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 9 | 11 | +2 |
| Shares | 81.6K | 276.3K | +194.7K (+238.5%) |
| Value | $157.9K | $483.5K | +$325.5K (+206.1%) |
New holders (5)
Institutions that held Innate Pharma SA at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 92,753 | $162.3K | 0.00% |
| Lion Point Capital, LP | 81,151 | $142.0K | 0.73% |
| Old Mission Capital LLC | 28,431 | $49.8K | 0.00% |
| Millennium Management LLC | 20,308 | $35.5K | 0.00% |
| SageView Advisory Group, LLC | 1 | $2 | 0.00% |
Sold out (3)
Institutions that held Innate Pharma SA at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Citadel Advisors LLC | 20,042 | $39.1K |
| Optiver Holding B.V. | 101 | $197 |
| Principal Securities, Inc. | 45 | $87 |